Aposense
- Company typePrivate
- Founded1996
- HeadquartersPetah Tiqva, Israel
- Headcount11–50
- GTM typeB2B
- OfferingServices
Aposense firmographics
Firmographics- Name
- Aposense
- Legal name
- Aposense Ltd.
- Website
- https://aposense.com
- Company type
- Private
- Founded year
- 1996
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Aposense industry classification
Industry- Product category
- Biopharmaceutical Drug Delivery Technology
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods) (HLAAACAC)
- akta.pro secondary industry
- mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC)
Keywords
Where Aposense is headquartered
LocationHeadquarters
- HQ city
- Petah Tiqva
- HQ country
- Israel
- HQ region
- Middle East
Markets served
Aposense business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Technology Licensing: Licensing the MNM platform technology to pharmaceutical companies for use in drug development across multiple therapeutic areas.
- Research Collaborations: Conducting research collaborations with pharmaceutical partners and institutions to advance MNM-based targeted delivery technologies.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
Aposense product offering
Product offeringCore offering
Aposense (rebranded to Interna Therapeutics in November 2024) develops the Molecular Nano-Motors (MNMs) platform, a proprietary intracellular delivery technology that transports large molecules — including DNA, RNA, proteins, and peptides — into cell cytoplasm by harnessing membrane electrical forces intrinsic to all cell membranes. The company focuses initially on infectious and non-infectious respiratory diseases (with an intranasal COVID-19 drug in Phase I trials) and pursues licensing partnerships with pharmaceutical companies alongside independent research collaborations.
Product overview
Aposense (now rebranded as Interna Therapeutics after its November 2024 merger with SirVir) is a biopharmaceutical company developing the Molecular Nano-Motors (MNMs) platform — a universal drug delivery technology for intracellular delivery of macromolecule therapeutics including DNA, RNA, proteins, and peptides. The company is pursuing partnerships to license this technology to pharmaceutical companies while conducting independent research, with a current focus on infectious and non-infectious respiratory diseases. The MNM platform is the core technology, and the company has an intranasal COVID-19 drug candidate in clinical development.
Differentiator
Problem solved
Functional benefit
Products and services
- Molecular Nano-Motors (MNMs) Platform A novel intracellular delivery technology that uses molecular nano-motors powered by the electrical forces intrinsic to all cell membranes to transport large molecule therapeutics — DNA, RNA, proteins, peptides — into the cell cytoplasm. It features a universal attachment system adaptable to broad molecular cargoes and supports multiple administration methods. Intended to be licensed to pharmaceutical companies for integration into their drug development programs across multiple therapeutic areas.
- Intranasal COVID-19 Drug (MNM-based) Lead therapeutic candidate built on the MNM platform for intranasal delivery to treat COVID-19 / SARS-CoV-2, leveraging the platform's intracellular delivery and nasal administration capabilities. Phase I clinical trial successfully completed in May 2025; a Human Challenge Trial Agreement with the University of Oxford (March 2026) supports further development of an intranasal MNM-siRNA SARS-CoV-2 prophylaxis program.
Quantifiable outcome
- Successfully completed Phase I clinical trial of intranasal COVID-19 drug
Companies that use Aposense
Customer profileSegments2 records
Ideal customer profiles1 record
Aposense technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Aposense partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Daiichi SankyocoreResearch collaboration to advance MNM-based targeted delivery technologies. This partnership leverages Daiichi Sankyo's pharmaceutical development capabilities with Interna Therapeutics' proprietary MNM platform for intracellular drug delivery.
- University of OxfordcoreHuman Challenge Trial Agreement to advance intranasal MNM-siRNA SARS-CoV-2 prophylaxis program. The collaboration advances novel prophylactic treatments for COVID-19 using the MNM platform for nasal drug delivery.
Scale indicators2 records
Recent moves6 records
Expansion highlights4 records
Aposense competitors and assessment
Company assessmentBroad incumbents
- CureVac: CureVac develops mRNA-based therapeutics using its proprietary RNActive platform and intranasal vaccine approaches. Comparable to Interna as an mRNA/infectious respiratory disease company with delivery expertise in nasal administration routes.
- BioNTech: BioNTech is a leading mRNA therapeutics company with proprietary LNP delivery capabilities used in its partnered COVID-19 vaccine. It is a broad incumbent in the nucleic acid delivery and intracellular delivery space.
- Translate Bio (Sanofi): Translate Bio developed an mRNA delivery platform and was acquired by Sanofi for ~$3.2B in 2021. While now part of a large incumbent, it historically mirrored Interna's strategy of licensing an mRNA delivery platform to a large pharma partner, making it a strong precedent comparable.
- Moderna: Moderna is a leading mRNA technology platform company with proprietary LNP delivery and broad therapeutic pipeline. As a large established player, it overlaps with Interna's nucleic acid delivery and licensing opportunity set.
Direct peers
- Genevant Sciences: Genevant develops LNP and other lipid-based delivery systems for RNA therapeutics and licenses its platform to pharma and biotech partners. It is directly comparable to Interna as a non-viral nucleic acid delivery platform pursuing technology licensing economics.
- Sirnaomics: Sirnaomics is a clinical-stage biopharma developing siRNA therapeutics with proprietary delivery platforms (PNP and GalNAc). It is directly comparable to Interna as a nucleic acid delivery platform company focused on intracellular delivery of macromolecules.
- Arcturus Therapeutics: Arcturus is a clinical-stage mRNA medicines and siRNA delivery company with proprietary LNP and delivery platforms and partnerships with pharma (e.g., CSL, Janssen). It competes with Interna in the intracellular RNA delivery space and shares the licensing/partnership business model.
- Acuitas Therapeutics: Acuitas is a Canadian specialist in lipid nanoparticle (LNP) delivery technology for nucleic acid therapeutics, including mRNA and siRNA. It is a direct competitor to Interna's MNM platform as both companies license intracellular delivery modalities to large pharma partners (e.g., Pfizer/BioNTech for Acuitas).
- Wave Life Sciences: Wave Life Sciences develops stereopure nucleic acid therapeutics including siRNA and antisense oligonucleotides with platform-level delivery expertise. Comparable to Interna as an oligonucleotide-focused delivery and development company with partnered programs.
Others
- Precision Nanosystems (Cytiva): Precision Nanosystems (now part of Cytiva) provides nanoparticle delivery technology, instrumentation and services for nucleic acid therapeutics development. It is adjacent/infrastructure rather than a direct competitor, but operates in the same intracellular delivery ecosystem as Interna.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights7 records
Customer concentration
Aposense social profiles
Digital presenceAposense financial estimates
Financial estimateRevenue estimate
Valuation estimate
Aposense leadership team
Management profileNumber of profiles
Profiles8 records
Aposense funding detail
Funding detailFunding overview
Funding rounds3 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Aposense M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Aposense
What does Aposense do?
Aposense (rebranded to Interna Therapeutics in November 2024) develops the Molecular Nano-Motors (MNMs) platform, a proprietary intracellular delivery technology that transports large molecules — including DNA, RNA, proteins, and peptides — into cell cytoplasm by harnessing membrane electrical forces intrinsic to all cell membranes. The company focuses initially on infectious and non-infectious respiratory diseases (with an intranasal COVID-19 drug in Phase I trials) and pursues licensing partnerships with pharmaceutical companies alongside independent research collaborations.
Is Aposense a public or private company?
Aposense is a private company. It is classified as venture growth investor backed and is currently operating.
When was Aposense founded?
Aposense was founded in 1996. It employs 11 to 50 people.
Where is Aposense based?
Aposense is headquartered in Petah Tiqva, Israel, in the Middle East region.
How does Aposense make money?
Two revenue lines are on record. Technology Licensing is the primary driver. The others are research Collaborations.
Who are Aposense's main competitors?
Broad incumbents on record are CureVac, BioNTech, Translate Bio (Sanofi) and Moderna. Direct peers are Genevant Sciences, Sirnaomics, Arcturus Therapeutics, Acuitas Therapeutics and Wave Life Sciences. Precision Nanosystems (Cytiva) is listed as an others.
Does Aposense have an API?
No public API is recorded for Aposense.
What industry is Aposense in?
Aposense's product category is Biopharmaceutical Drug Delivery Technology. Its primary akta.pro industry code is HLAAACAC, Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods), with a secondary code of HLAGAGAC, mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA). Its NAICS code is 541714 and its SIC code is 2834.